Marksans Pharma Limited — Investor Meet, 12-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Marksans Pharma reported strong financial results for the quarter and half-year, with Q3 FY26 operating revenue at INR 754 Cr (+10.6% YoY) and EBITDA up 23.2% to INR 160.7 Cr, driven by improved cost efficiencies and margin expansion to 21.3%. The US market saw robust growth, supported by a $220M+ order book. The UK business is stabilizing, aided by new product launches. The company is strategically expanding globally, incorporating subsidiaries in Ireland and Canada, and actively pursuing M&A in Europe. Management expressed confidence in achieving INR 4,000 Cr revenue within 2-3 years, fueled by consistent market share gains and pipeline execution.